Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences (NASDAQ: ANIX) has been awarded U.S. Patent Number 12,370,244, extending protection for its breast cancer vaccine technology into the mid-2040s. The patent covers novel immunization methods using human 伪-濒补肠迟补濒产耻尘颈苍 protein, which is expressed during lactation and in certain breast cancers.
Developed in collaboration with Cleveland Clinic, this vaccine represents a pioneering approach to breast cancer prevention, targeting a significant unmet need. With 297,000 new cases of invasive breast cancer projected in 2025 and 43,000 expected deaths in the U.S., the technology addresses a potential multi-billion dollar market opportunity, particularly for women at risk of triple-negative breast cancer (TNBC).
Anixa Biosciences (NASDAQ: ANIX) ha ottenuto il brevetto statunitense numero 12.370.244, che estende la protezione per la sua tecnologia di vaccino contro il cancro al seno fino alla met脿 degli anni '40 del 2040. Il brevetto riguarda nuovi metodi di immunizzazione che utilizzano la proteina umana 伪-lattalbumina, espressa durante l'allattamento e in alcuni tipi di cancro al seno.
Sviluppato in collaborazione con la Cleveland Clinic, questo vaccino rappresenta un approccio innovativo alla prevenzione del cancro al seno, rispondendo a un bisogno ancora insoddisfatto. Con 297.000 nuovi casi di cancro al seno invasivo previsti per il 2025 e 43.000 decessi attesi negli Stati Uniti, questa tecnologia si rivolge a un鈥檕pportunit脿 di mercato potenzialmente multimiliardaria, in particolare per le donne a rischio di carcinoma mammario triplo negativo (TNBC).
Anixa Biosciences (NASDAQ: ANIX) ha recibido la patente estadounidense n煤mero 12,370,244, que extiende la protecci贸n de su tecnolog铆a de vacuna contra el c谩ncer de mama hasta mediados de la d茅cada de 2040. La patente cubre nuevos m茅todos de inmunizaci贸n que utilizan la prote铆na humana 伪-濒补肠迟补濒产耻尘颈苍a, la cual se expresa durante la lactancia y en ciertos c谩nceres de mama.
Desarrollada en colaboraci贸n con la Cleveland Clinic, esta vacuna representa un enfoque pionero para la prevenci贸n del c谩ncer de mama, abordando una necesidad significativa no cubierta. Con 297,000 nuevos casos de c谩ncer de mama invasivo proyectados para 2025 y 43,000 muertes esperadas en EE.UU., la tecnolog铆a apunta a una oportunidad de mercado multimillonaria, especialmente para mujeres en riesgo de c谩ncer de mama triple negativo (TNBC).
Anixa Biosciences (NASDAQ: ANIX)臧� 氙戈淡 韸鬼棃 氩堩樃 12,370,244毳� 須嶋摑頃橃棳 鞙犽癌鞎� 氚膘嫚 旮办垹鞐� 雽�頃� 氤错樃 旮瓣皠鞚� 2040雲勲寑 欷戨皹旯岇 鞐办灔頄堨姷雼堧嫟. 鞚� 韸鬼棃電� 靾橃湢 欷� 氚� 韸轨爼 鞙犽癌鞎旍棎靹� 氚滍槃霅橂姅 鞚戈皠 伪-霛巾儉鞎岆秬氙� 雼氨歆�鞚� 鞚挫毄頃� 靸堧鞖� 氅挫棴頇� 氚╇矔鞚� 韽暔頃╇媹雼�.
韥措Μ敫旊灉霌� 韥措Μ雼夑臣 順戨牓頃橃棳 臧滊皽霅� 鞚� 氚膘嫚鞚� 鞙犽癌鞎� 鞓堧癌鞐� 鞛堨柎 靹犼惮鞝侅澑 鞝戧芳氩曥潉 鞝滌嫓頃橂┌, 欷戩殧頃� 氙胳订臁� 靾橃殧毳� 瓴儱頃╇媹雼�. 2025雲勳棎 297,000瓯挫潣 靸堧鞖� 旃姷靹� 鞙犽癌鞎� 靷鞕赌 43,000氇呾潣 靷鞛�臧� 氙戈淡鞐愳劀 鞓堨儊霅橂姅 臧�鞖措嵃, 鞚� 旮办垹鞚� 韸鬼瀳 靷检鞚岇劚 鞙犽癌鞎�(TNBC) 鞙勴棙鞚� 鞛堧姅 鞐劚霌れ潉 鞙勴暅 靾橃嫮鞏� 雼煬 攴滊鞚� 鞁滌灔 旮绊殞毳� 鞝滉车頃╇媹雼�.
Anixa Biosciences (NASDAQ : ANIX) s鈥檈st vu attribuer le brevet am茅ricain num茅ro 12 370 244, prolongeant la protection de sa technologie de vaccin contre le cancer du sein jusqu鈥檃u milieu des ann茅es 2040. Le brevet couvre des m茅thodes d鈥檌mmunisation innovantes utilisant la prot茅ine humaine 伪-濒补肠迟补濒产耻尘颈苍e, exprim茅e durant la lactation et dans certains cancers du sein.
D茅velopp茅 en collaboration avec la Cleveland Clinic, ce vaccin repr茅sente une approche pionni猫re dans la pr茅vention du cancer du sein, r茅pondant 脿 un besoin important non satisfait. Avec 297 000 nouveaux cas de cancer du sein invasif pr茅vus en 2025 et 43 000 d茅c猫s attendus aux 脡tats-Unis, cette technologie cible une opportunit茅 de march茅 potentiellement de plusieurs milliards de dollars, notamment pour les femmes 脿 risque de cancer du sein triple n茅gatif (TNBC).
Anixa Biosciences (NASDAQ: ANIX) wurde das US-Patent Nummer 12.370.244 erteilt, das den Schutz f眉r seine Brustkrebs-Impfstofftechnologie bis Mitte der 2040er Jahre verl盲ngert. Das Patent umfasst neuartige Immunisierungsmethoden unter Verwendung des menschlichen 伪-Laktalbumin-Proteins, das w盲hrend der Laktation und bei bestimmten Brustkrebserkrankungen exprimiert wird.
In Zusammenarbeit mit der Cleveland Clinic entwickelt, stellt dieser Impfstoff einen bahnbrechenden Ansatz zur Brustkrebsvorsorge dar und adressiert einen bedeutenden ungedeckten Bedarf. Mit 297.000 neuen F盲llen von invasivem Brustkrebs, die f眉r 2025 prognostiziert werden, und 43.000 erwarteten Todesf盲llen in den USA, bietet die Technologie eine potenzielle Milliardenmarktchance, insbesondere f眉r Frauen mit Risiko f眉r triple-negativen Brustkrebs (TNBC).
- Patent protection extended into mid-2040s for breast cancer vaccine technology
- Addresses multi-billion dollar market opportunity in preventive oncology
- Targets unmet need with no current FDA-approved breast cancer prevention vaccine
- Potential broader applications beyond high-risk populations
- Vaccine still in early development stages
- Clinical efficacy and regulatory approval yet to be demonstrated
Insights
Anixa's new patent significantly strengthens their breast cancer vaccine IP portfolio, extending protection into the 2040s for a potential multi-billion dollar market.
This patent issuance represents a substantial strengthening of Anixa's intellectual property position for their breast cancer vaccine technology. The new patent (No. 12,370,244) specifically covers methods of immunizing against breast cancer using human 伪-濒补肠迟补濒产耻尘颈苍 protein compositions. This is strategically significant as it extends protection into the mid-2040s, providing nearly two decades of market exclusivity for their potential commercial product.
The patent's value lies in its coverage of a unique immunoprevention approach targeting 伪-濒补肠迟补濒产耻尘颈苍鈥攁 protein normally expressed during lactation but also found in certain breast cancers. This creates an elegant targeting mechanism: since this protein is essentially "retired" in normal adult tissues except during lactation, it offers a way to potentially target cancer cells while minimizing off-target effects.
What makes this particularly valuable is the expanded claims covering immunogenic formulations, which broadens Anixa's protection beyond basic methods to include various potential product formulations. This comprehensive IP coverage is critical for a technology addressing the substantial breast cancer market鈥攐ver 297,000 new invasive cases projected in 2025 in the US alone.
For investors, this patent strengthens Anixa's competitive positioning in preventive oncology, particularly for high-risk populations such as those susceptible to triple-negative breast cancer, where treatment options remain limited. The lack of any FDA-approved breast cancer vaccine creates a significant first-mover opportunity in what the company identifies as a multi-billion dollar market.
Patent Expands Immunogenic Coverage of 伪-Lactalbumin-Based Vaccine Platform
Technology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market Potential
Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to the prevention and treatment of breast cancer. The vaccine was invented at Cleveland Clinic, and this patent鈥攁long with others related to this technology鈥攈as been exclusively licensed to Anixa Biosciences. This issuance builds upon the Company's broad and expanding intellectual property portfolio, extending foundational patent protection for the breast cancer vaccine program into the mid-2040s. The expanded claims provide additional coverage for immunogenic formulations, further enhancing Anixa's ability to develop and commercialize differentiated immunopreventive solutions.
Despite significant progress in breast cancer treatment, the disease remains the most commonly diagnosed cancer among women worldwide. In
Anixa's investigational vaccine aims to stimulate the immune system to recognize and eliminate pre-malignant and malignant cells expressing 伪-濒补肠迟补濒产耻尘颈苍鈥攚hile sparing normal tissue. By targeting this "retired" protein, which is generally absent from adult tissues except during lactation, the vaccine has the potential to minimize off-target effects and provide long-lasting immune protection.
The breast cancer vaccine platform represents a potential multi-billion dollar market opportunity, particularly among women at elevated risk of developing triple-negative breast cancer (TNBC)鈥攁n aggressive subtype with limited treatment options and poor long-term prognosis. As clinical data and regulatory frameworks evolve, the technology may also have broader applications for average-risk populations.
"Our breast cancer vaccine program is a cornerstone of our long-term strategy to develop next-generation preventive immunotherapies, and this patent issuance further secures our leadership in this field," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "With a robust portfolio of issued and pending patents in the
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit 聽or follow Anixa on , , and .
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808
View original content to download multimedia:
SOURCE Anixa Biosciences, Inc.
FAQ
What is the significance of Anixa's new breast cancer vaccine patent (NASDAQ: ANIX)?
How does Anixa's breast cancer vaccine work?
What is the market potential for Anixa's breast cancer vaccine?
Who developed Anixa's breast cancer vaccine technology?
What makes Anixa's breast cancer vaccine unique?
